Skip to main content

Table 4 Major AEs of Targeted Therapies for CNS Lymphoma

From: Current and emerging therapies for primary central nervous system lymphoma

Targeted therapy Adverse events
Events Any grade Grade≥3
ibrutinib [14, 70,71,72] neutropenia 25%(5/20)~40%(6/15), 3.8%(2/52)~ 83%(15/18)
anemia 70%(14/20)~100%(15/15) 5%(1/20)~20%(3/15)
thrombocytopenia 70%(14/20) 10%(2/20)~72%(13/18)
febrile neutropenia 5%(1/25) 1.9%(1/52)~61%(11/18)
increased creatinine 27%(4/15)~30%(6/20) 27%(4/15)
increased ALT 3.8%(2/52)~80%(12/15) 7%(1/15)~10%(2/20)
diarrhea 3.8%(2/52)~25%(5/20) 7%(1/15)~11%(2/18)
prolonged APTT 20%(3/15)~30%(6/20) 10%(2/20)
infection 9.6%(5/52)~27%(4/15) 5.8%(3/52)~78%(14/18)
atrial fibrillation 3.8%(2/52) 1.9%(1/52)
lenalidomide [42, 76] neutropenia   21.4%(3/14)~40%(20/50)
thrombocytopenia   10%(5/50)
anemia   4%(2/50)
infection   8%(4/50)~21.4%(3/14)
Pomalidomide [15] neutropenia 100%(25/25) 20%(5/25)
thrombocytopenia 44%(11/25) 8%(2/25)
anemia 80%(20/25) 8%(2/25)
thromboembolism 8%(2/25)  
infection 44%(11/25) 16%(4/25)
fatigue 40%(10/25) 8%(2/25)
dyspnea, hypoxia and/or respiratory failure 16%(4/25) 16%(4/25)
nivolumab [77] pruritus 20%(1/5)  
fatigue 20%(1/5)  
renal insufficiency 20%(1/5) 20%(1/5)
NGR-hTNF [78] neutropenia 89%(25/28) 85%(24/28)
thrombocytopenia 85%(24/28) 61%(17/28)
anemia 85%(24/28) 21%(6/28)
febrile neutropenia 14%(4/28) 14%(4/28)
infection 14%(4/28) 14%(4/28)
deep vein thrombosis 7%(2/28) 7%(2/28)
infusion reaction 32%(9/28)  
hepatotoxicity 50%(14/28) 18%(5/28)
  1. Abbreviations: ALT alanine aminotransferase, APTT activated partial thromboplastin time